What Is Survodutide?
Survodutide (BI 456906) is a once-weekly injectable dual agonist of GLP-1 and glucagon receptors developed by Boehringer Ingelheim and Zealand Pharma. Sharing the dual GLP-1/glucagon mechanism with Mazdutide, survodutide is being evaluated primarily for obesity and metabolic dysfunction-associated steatohepatitis (MASH/NASH) — leveraging glucagon receptor agonism's unique capacity to directly reduce hepatic fat accumulation.
Dual Mechanism: GLP-1 + Glucagon
GLP-1 receptor agonism provides appetite suppression, glucose-dependent insulin stimulation, and reduced gastric emptying. Glucagon receptor agonism adds thermogenic energy expenditure, hepatic fatty acid oxidation (directly reducing liver fat), and lipolysis from adipose tissue. The GLP-1 component prevents the hyperglycemia that pure glucagon agonism would cause — the fundamental design logic of dual GLP-1/glucagon compounds.
Clinical Data
Phase 2 trials in obesity reported approximately 15% body weight reductions at 46 weeks at the highest dose tested. In MASH-specific trials, liver fat reduction was particularly pronounced compared to semaglutide — supporting the hypothesis that glucagon receptor co-agonism adds meaningful hepatic benefit beyond what GLP-1 alone achieves. Phase 3 trials in MASH and obesity are ongoing.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Phase 2 Obesity Trial Without Diabetes (2024)
Human | 0.6-4.8mg weekly | 46 weeks | Up to 14.9% weight loss - Phase 2 MASH and Fibrosis Trial (2024)
Human | 2.4-6.0mg weekly | 48 weeks | 47-62% MASH improvement - Phase 2 Type 2 Diabetes Trial (2023)
Human | 0.3-2.7mg weekly | 16 weeks | Superior to semaglutide - Preclinical Pharmacology Study (2022)
Animal/In vitro | Various doses | EC50 0.52nM GCGR, 0.33nM GLP-1R - A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal AJ, Bedossa P, Fraessdorf M, 2024, N Engl J Med - Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker DJ, 2024, Diabetes Care - Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis M, Chakhtoura M, Rhayem C, 2025, Pharmacol Rev - Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
Lawitz EJ, Fraessdorf M, Neff GW, 2024, J Hepatol - Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW, Steen O, Lucas KJ, 2024, Lancet Diabetes Endocrinol